During 2017 and 2018, states took the reins in terms of enacting laws compelling drug manufacturers to disclose drug pricing. State activity has slowed during the first six months of 2019. Instead, during the first half of 2019, the federal government has led the way on a variety of healthcare and drug pricing transparency initiatives. After a brief review of these federal initiatives, this article discusses state laws requiring drug manufacturers to report pricing and other related information. Thereafter, the article reviews previously enacted state laws imposing manufacturer price reporting obligations to assess the impact these laws have had on drug prices in the applicable state.
Originally published in the November 2019 issue of Pratt’s Government Contracting Law Report (Vol. 5, No. 11).
Please see full publication below for more information.
